• CHECKOUT
  • English
  • German
  • US Dollar
  • Euro
  • UK Pound
  • Canadian Dollar
  • Swiss Frank
  • Australian Dollar
0 items
Cart Contents

Laboratory tests when using Halotestin (fluoxymesterone)

Women should be observed for signs of virilization which is usual following androgen use at high doses. Discontinuation of drug therapy at the time of evidence of mild virilism is necessary to prevent irreversible virilization. A decision may be made by the patient and the physician that some virilization will be tolerated during treatment for breast carcinoma.

Women with disseminated breast carcinoma should have frequent determination of urine and serum calcium levels during the course of androgen therapy.

Because of the hepatotoxicity associated with the use of 17-alpha-alkylated androgens, liver function tests should be obtained periodically.

Periodic (every six months) X-ray examinations of bone age should be made during treatment of prepubertal males to determine the rate of bone maturation and the effects of androgen therapy on the epiphyseal centers.

Hemoglobin and hematocrit levels (to detect polycythemia) should be checked periodically in patients receiving long-term androgen administration.

Serum cholesterol may increase during androgen therapy.

Products related to this article:

Halotestin - Halobolic